Oncological outcomes of squamous cell carcinoma of the cervical esophagus treated with definitive (chemo-)radiotherapy: a systematic review and meta-analysis

Costantino, Andrea; Festa, Bianca Maria; Mercante, Giuseppe; Franceschini, Davide; Franzese, Ciro; Scorsetti, Marta; Marrari, Andrea; Cavina, Raffaele; Marano, Salvatore; Castoro, Carlo; Spriano, Giuseppe

doi:10.1007/s00432-022-03965-8

Cited by 7 publications

(5 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median OS was 33.4 months (25.8-42.2). [8] In the present study, the estimated 2-year and 5-year OS rates were 42.2% and 21.1%, respectively, which were slightly lower than those mentioned in the meta-analysis.…”

Section: Discussioncontrasting

confidence: 72%

“…[1][2][3][4] Cervical esophageal cancer can be detected in a wide age range (18-87). [8] The age distribution of our study cohort was between 37 and 69 years. Men were the most commonly affected patient group in most studies as in ours (60%).…”

Section: Discussionmentioning

confidence: 99%

“…[2][3][4] In earlier research, the locoregional failure (LRF) rate ranged from 12 to 50%, while the 5-year overall survival (OS) rate following chemoradiotherapy (CRT) for CEC was between 18 and 54%. [4][5][6][7][8] The aim of this study is to analyze the survival outcome in patients with cervical esophageal cancer treated with chemoradiotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Yoğunluk Ayarlı veya 3 Boyutlu Konformal Radyasyon Tedavisi Kullanılarak Definitif Kemoradyoterapi İle Tedavi Edilen Servikal Özofagus Kanserinin Sağkalım Sonuçları: Tek Merkez Deneyimi

DUZOVA

Basaran

Eren

et al. 2023

Journal of Contemporary Medicine

View full text Add to dashboard Cite

Abstract Objective: The aim of this study is to report the survival and treatment results of patients with cervical esophageal cancer treated with definitive chemoradiotherapy, whose incidence is very low in the population and there is not enough information about treatment and toxicity results in the literature. Material and Method: Between 2013 and 2022, 10 patients (six males and four females) with cervical esophageal cancer treated with definitive chemoradiotherapy were included. Among these patients, seven had stage II disease, one stage III, and 2 stage IVA. All patients received radiotherapy at a median dose of 50.4 Gy and concurrent weekly chemotherapy. Results: The median follow-up period was 18 months. The two-year and 5-year overall survival rates were 42.2% and 21.1%, respectively. The two-year and 5-year disease-free survival rates were 45.7% and 22.9%, respectively. Disease progression was noted in 3 out of 10 patients (30%). Three patients were still alive during analyze. Percutaneous enteral gastrostomy was performed in 3 of 10 patients. These requirement occured in 1 due to local progression, and in the remaining 2 patients due to the side effect of RT. Conclusions: Overall survival rates were low, as similar findings appear in the literature. It was remarkable that the need for a percutaneous enteral gastrostomy was not observed in the IMRT group. All patients with complete remission were in stage 2.

show abstract

Section: Discussioncontrasting

confidence: 72%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Yoğunluk Ayarlı veya 3 Boyutlu Konformal Radyasyon Tedavisi Kullanılarak Definitif Kemoradyoterapi İle Tedavi Edilen Servikal Özofagus Kanserinin Sağkalım Sonuçları: Tek Merkez Deneyimi

DUZOVA

Basaran

Eren

et al. 2023

Journal of Contemporary Medicine

View full text Add to dashboard Cite

show abstract

“…6 Most studies, including case series and RCTs examining the efficacy of dCRT in treating esophageal malignancies, are either in mixed populations of SCC and AC or, in studies dedicated to SCCs, a mixed population of cervical and thoracic SCC. 10 Therefore, the optimal dCRT approach for cervical SCC is open to debate. Many centers favor using cisplatin and 5-FU for systemic treatment in higher doses than typically used as neoadjuvant therapy for resectable thoracic esophageal cancer, with 5-year overall survival rates of 35.5% (29.7-41.9).…”

Section: Current Management Of Cervical Esophageal Tumorsmentioning

confidence: 99%

“…Many centers favor using cisplatin and 5-FU for systemic treatment in higher doses than typically used as neoadjuvant therapy for resectable thoracic esophageal cancer, with 5-year overall survival rates of 35.5% (29.7-41.9). 10 Other regimens used include FOLFOX, and other combination platinum-based therapies, such as carboplatin/docetaxel. 11,12 These show acceptable short- and long-term survival and may have more favorable side-effect profiles when compared with cisplatin/5FU.…”

Section: Current Management Of Cervical Esophageal Tumorsmentioning

confidence: 99%